Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06494878 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

The PARTUM Trial: Postpartum Aspirin to Reduce Thromboembolism Undue Morbidity

StatusRecruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Recruitment openedv3 Show 4 more changesShow less
    • Start date changed from estimate of Apr 2025 to Jun 4, 2026
    • Trial sites expanded: 3 → 12 locations
    • Primary completion pushed from Aug 2030 to Sep 2030
    • Collaborators: 1 to 2
  2. Start date: Sep 2024 to Apr 2025v2
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The goal of the PARTUM trial is to determine if taking low-dose aspirin daily for 6 weeks after delivery is similar (non-inferior) to usual care low-molecular-weight heparin injections to prevent venous thromboembolism (VTE: blood clots in the legs or lungs) for postpartum individuals with VTE risk factors.
Trial Details
NCT Number NCT06494878
Lead Sponsor University of Calgary
Collaborators: Canadian Institutes of Health Research (CIHR), European Clinical Research Infrastructure Network
Conditions
(from sponsor)		 Venous Thromboembolism, Postpartum Period, Aspirin, Low Molecular Weight Heparin
Related terms Postpartum Hemorrhage, Pre-Eclampsia, Pulmonary Embolism, Thrombophilia, Venous Thromboembolism, Venous Thrombosis
Enrollment 8,805 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov